LABT NASDAQ
Lakewood-Amedex Biotherapeutics, Inc.
1W: -44.2%
1M: -55.0%
3M: -66.0%
YTD: -90.7%
$0.93
+0.00 (+0.27%)
Weekly Expected Move ±22.5%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.6M
52W Range0.91-98.2
Volume99,678
Avg Volume1,716,095
Beta-4.76
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOKelvin Cooper
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2026-04-23
Websitelakewoodamedex.com
8031 Cooper Creek Blvd., Unit 103
University Park, FL 34201
US
University Park, FL 34201
US
1-941-225-2515
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Recent Insider Trades
No insider trades found